Cyclophosphamide and Tamoxifen in Breast Cancer Treatment
Author Information
Author(s): W.P. Abram, M. Baum, D.A. Berstock, D. Brinkley, J. Cuzick, K.R. Durrant, C. Elston, J.R. Farndon, J. Houghton, A.R. Lyons, J. MacIntyre, K.D. MacRae, G.W. Odling-Smee, N.W.M. Orr, M. Perry, R. Peto, R. Phillips, T.J. Powles, D.L. Riley, W. Ross, D. Roy, I. Smith, C. Teasdale, J.S. Tobias
Primary Institution: Cancer Research Campaign
Hypothesis
Does the combination of cyclophosphamide and tamoxifen improve event-free survival in early breast cancer patients?
Conclusion
The study found that both cyclophosphamide and tamoxifen significantly improve event-free survival in early breast cancer patients.
Supporting Evidence
- Tamoxifen treatment resulted in significantly fewer events compared to the control group.
- Cyclophosphamide also showed a significant reduction in events compared to the control group.
- Both treatments improved event-free survival in premenopausal and postmenopausal patients.
Takeaway
This study shows that two medicines, cyclophosphamide and tamoxifen, can help women with early breast cancer live longer without their cancer coming back.
Methodology
Women with stage I or II breast cancer were randomized into four treatment groups: control, tamoxifen, cyclophosphamide, or a combination of both.
Potential Biases
Potential biases in patient selection and treatment allocation could affect the results.
Limitations
The follow-up period was relatively short, and the study may not have captured long-term survival benefits.
Participant Demographics
Women under 75 years of age with stage I or II breast cancer.
Statistical Information
P-Value
P<0.001 for tamoxifen; P=0.045 for cyclophosphamide
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website